Table 1.

Baseline characteristics of study patients^*

Characteristic	Group A	Group B	P †
	(n = 126)	(n = 124)
Sex, female	97 (77)	94 (75.8)	0.826
Age at JIA onset, median (IQR) years	4 (2.2–6.8)	4.2 (2.0–6.9)	0.71‡
Age at V1, median (IQR) years§	10.9 (7.8–14.4)	10.9 (8.0–14.4)	0.933‡
Disease duration at V1, median (IQR) years§	5.1 (3.2–8.6)	5.3 (2.7–8.5)	0.809‡
JIA subtype
Oligoarticular	83 (65.8)	77 (62.1)	0.534
Polyarticular	35 (27.8)	41 (33.1)	0.364
Systemic	7 (5.6)	4 (3.2)	0.369
ERA	1 (0.8)	2 (1.6)	0.62¶
ANA positivity	58 (46)	52 (41.9)	0.514
History of uveitis	28 (22.2)	26 (21)	0.81
Past JIA treatment
Intraarticular glucocorticoid injections	45 (35.7)	40 (32.3)	0.564
Systemic glucocorticoids	21 (16.7)	18 (14.5)	0.639
Methotrexate	54 (42.9)	65 (52.4)	0.13
Other conventional DMARDs	3 (2.4)	2 (1.6)	1.0¶
Biologic DMARDs	14 (11.1)	16 (12.9)	0.663
Ongoing JIA treatment at V1§
NSAIDs	17 (13.5)	8 (6.5)	0.064
Systemic glucocorticoids	0	1 (0.8)	0.496¶
Methotrexate	59 (46.8)	46 (37.1)	0.119
Sulfasalazine	1 (0.8)	2 (1.6)	0.62¶
Biologic DMARDs	55 (43.7)	56 (45.2)	0.81
Etanercept	28 (22.2)	27 (21.8)	0.932
Adalimumab	15 (11.9)	14 (11.3)	0.879
Infliximab	2 (1.6)	3 (2.4)	0.682¶
Tocilizumab	7 (5.6)	9 (7.3)	0.582
Canakinumab	0	1 (0.8)	0.496¶
Abatacept	3 (2.4)	2 (1.6)	1.0¶
Off‐therapy	20 (15.9)	28 (22.6)	0.178
Out‐of‐school physical activity in the last month, no./total no. (%)#	50/91 (54.9)	50/92 (54.3)	0.9

^*Values are the number (%) unless indicated otherwise. ANA = antinuclear antibody; DMARDs = disease‐modifying antirheumatic drugs; ERA = enthesitis‐related arthritis; IQR = interquartile range; JIA = juvenile idiopathic arthritis; NSAIDs = nonsteroidal antiinflammatory drugs.

^†By chi‐square test unless otherwise specified.

^‡By Mann‐Whitney U test.

^§V1 frame was from September 1, 2018 to March 9, 2019 in group A; and from September 1, 2019 to March 9, 2020 in group B.

^¶By Fisher's exact test.

^#Data on sports activity outside school were available for 91 patients in group 1 and for 92 patients in group 2.